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The generation and transmission of the 
information in the central nervous system 
(CNS) strongly rely on the structural and 
functional framework formed by neuronal 
cells. However, astrocytes, the major glial 
cell type, may profoundly impact on the 
performance of the framework, as they 
give metabolic and trophic support to 
neurons, and regulate synapse formation 
and function.1 Under pathological set-
tings astrocytes rapidly respond to injury 
by promoting the formation of scar tissue 
and supporting local acute inflammatory 
reactions—both aspects are essential to 
confine the lesions, repair the damage and 
restore tissue homeostasis.1-3 Clearly, dys-
regulation of astrocyte activities may be 
dangerous for CNS function.
In multiple sclerosis (MS), an inflam-
matory neurodegenerative disorder of the 
CNS, chronic lesions are characterized by 
permanent demyelination and neurode-
generation. Here, we observed the upregu-
lation of the neurotrophin receptor TrkB 
on astrocytes (Fig. 1).4
Neurotrophins constitute a family of 
growth factors including NGF, BDNF, 
NT3 and NT4/5. Since they are impor-
tant for survival, differentiation and func-
tion of neurons,5 neurotrophins have been 
regarded as beneficial for neuroprotection 
and neuroregeneration.
Similarly to human MS lesions, astro-
cyte TrkB was strongly upregulated also 
in experimental autoimmune encephalo-
myelitis (EAE), the animal model of MS, 
indicating that neuroinflammation makes 
astrocytes more sensitive to neurotrophin 
action. Interestingly, the main TrkB vari-
ant detected in astrocytes both in MS and 
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EAE tissues was the truncated TrkB-T1 
isoform,4 which results from alternative 
splicing of the TrkB gene and activates 
intracellular signaling pathways in glial 
cells despite lacking the tyrosine kinase 
domain.6
To address the contribution of astrocyte 
TrkB to neuroinflammation we analyzed 
EAE expression in double transgenic mice 
in which TrkB was excised in astrocytes.7 
Surprisingly, transgenic mice showed 
ameliorated disease, reduced immune cell 
infiltration and negligible levels of neuro-
degeneration when compared with control 
animals, indicating a detrimental role for 
astrocyte TrkB in neuroinflammation and 
neurodegeneration.
To investigate the effects of neuro-
trophins on astrocyte-neuron interaction, 
we developed an in vitro model in which 
rat spinal neurons were exposed to condi-
tioned media from human astrocytes. A 
series of live imaging and immunofluo-
rescence experiments on neuronal cul-
tures showed that low concentrations of 
the neurotrophin BDNF had no direct 
effects on neurons, while it activated 
astrocytes to release factors which induced 
rapid disruption of the neuronal network 
and apoptosis. Interestingly, similarly to 
BDNF, two more TrkB ligands, NT3 
and NT4, triggered neurodegeneration 
when given to astrocytes. This phenom-
enon depended on astrocyte TrkB, as 
TrkB-knockout astrocytes were unable 
to generate media in response to BDNF 
which induced neuronal fragmentation 
and death.4
The neurotoxic mediator released by 
astrocytes was nitric oxide (NO) (Fig. 1). 
In fact, live imaging experiments on cells 
loaded with the NO indicator DAF-FM 
clearly showed TrkB-dependent NO 
synthesis in BDNF-treated astrocytes.4 
Furthermore, neurodegeneration was 
hampered upon blockade of NO syn-
thases either in astrocytes or in neurons, 
indicating that the phenomenon is trig-
gered by astrocyte NO and sustained by 
neuronal NO. NO regulates homeostatic 
and physiological functions in the CNS, 
like neuronal survival and differentiation, 
synaptic activity and neural plasticity. The 
inducible NO synthase (iNOS), which is 
physiologically expressed at low levels, is 
strongly upregulated under inflammatory 
settings, and excessive levels of NO lead 
to formation of reactive nitrogen species, 
tyrosine nitrosylation of intracellular pro-
teins and cell death.8 As expected, iNOS 
and nitrosylated proteins were strongly 
detected in the spinal cord of control EAE 
mice. In contrast, in vivo depletion of 
astrocyte TrkB impaired iNOS expression 
and nitrotyrosine deposition,4 indicating 
that the TrkB signaling in glial cells is 
fundamental for the production of NO in 
injured CNS.
In conclusion, these data suggest that 
in MS the upregulation of TrkB on astro-
cytes contributes to neuronal damage via 
NO production (Fig. 1). The observa-
tion that neurotrophins may promote 
neurodegeneration through the astrocyte 
raises caution on the potential therapy 
of CNS disorders with these growth fac-
tors. However, it supports the rationale for 
the development of novel neuroprotective 
therapies, which target glial cells rather 
than neurons.© 2012 Landes Bioscience.
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Figure 1. Proposed model for astrocyte trkB-t1 induced neurodegeneration. (1) astrocytes up-
regulate trkB-t1 in Ms and EaE and become responsive to neurotrophins (yellow, blue, green dots 
for BdNF, Nt3, Nt4 respectively). trkB signaling in astrocytes results in enhanced iNos expression 
(2) and consequently, No synthesis and release (3). astrocyte No triggers a secondary No boost in 
neurons (4), leading to protein nitrosylation (5), neuronal fragmentation (6) and apoptosis (7).